Cargando…

Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials

Hepatocellular carcinoma (HCC) is a prevalent primary liver cancer, representing approximately 85% of cases. The diagnosis is often made in the middle and late stages, necessitating systemic treatment as the primary therapeutic option. Despite sorafenib being the established standard of care for adv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Jiahui, Li, Mengnan, Ren, Boxu, Cheng, Le, Wang, Xiaoxiao, Ma, Zhaowu, Yong, Wei Peng, Chen, Xiaoguang, Wang, Lingzhi, Goh, Boon Cher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501787/ https://www.ncbi.nlm.nih.gov/pubmed/37719852 http://dx.doi.org/10.3389/fphar.2023.1261575

Ejemplares similares

Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?
por: Ma, Zhaowu, et al.
Publicado: (2021)

The potential role of exosomal circRNAs in the tumor microenvironment: insights into cancer diagnosis and therapy
por: Li, Juan, et al.
Publicado: (2022)

The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
por: Li, Ji, et al.
Publicado: (2022)

Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma
por: Le, Thi Bich Uyen, et al.
Publicado: (2020)

The battle of Alzheimer’s Disease – the beginning of the future Unleashing the potential of academic discoveries
por: Lundkvist, Johan, et al.
Publicado: (2014)

Case Series of Steroid-Resistant Immune Checkpoint Inhibitor Associated Myocarditis: A Comparative Analysis of Corticosteroid and Tofacitinib Treatment
por: Wang, Cong, et al.
Publicado: (2021)

A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma
por: Guan, Renguo, et al.
Publicado: (2022)

Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota
por: Hu, Zishuo Ian, et al.
Publicado: (2022)

Development and Validation of a Prognostic Score for Hepatocellular Carcinoma Patients in Immune Checkpoint Inhibitors Therapies: The Hepatocellular Carcinoma Modified Gustave Roussy Immune Score
por: Li, Yongjiang, et al.
Publicado: (2022)

Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy
por: Grottoli, Melania, et al.
Publicado: (2022)

Resistance to immune checkpoint inhibitors in gastric cancer
por: Liu, Kai, et al.
Publicado: (2023)

Acceptance rate of clinical pharmacists’ recommendations—an ongoing journey for integration
por: Peled, Orit, et al.
Publicado: (2023)

Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge
por: Catalano, Martina, et al.
Publicado: (2022)

Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging future
por: Zhang, Zeng, et al.
Publicado: (2022)

Different treatment efficacies and side effects of cytotoxic chemotherapy
por: Li, Low-Jia, et al.
Publicado: (2020)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Wang, Di, et al.
Publicado: (2021)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma
por: Chen, Xi, et al.
Publicado: (2022)

Clinical Insights Into Novel Immune Checkpoint Inhibitors
por: Lee, Jii Bum, et al.
Publicado: (2021)

Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China
por: Fang, Wenfeng, et al.
Publicado: (2019)

Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
por: Yan, Xinyu, et al.
Publicado: (2018)

Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19
por: Saha, Rudra P., et al.
Publicado: (2020)

A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Liao, Dan, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors Plus an Anti-VEGF Antibody as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis
por: Li, Lu, et al.
Publicado: (2022)

Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis
por: Zhang, Tian, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management
por: Wang, Haiyang, et al.
Publicado: (2019)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
por: Shen, Pan, et al.
Publicado: (2021)

Drug therapy for myocarditis induced by immune checkpoint inhibitors
por: Wu, Yihao, et al.
Publicado: (2023)

Unleash quality: build a winning strategy for a culture of quality that will unleash your growth and profit potential
por: Angle, Arron S
Publicado: (2019)

Metabolic Reprogramming of Sulfur in Hepatocellular Carcinoma and Sulfane Sulfur-Triggered Anti-Cancer Strategy
por: Zhang, Ximing, et al.
Publicado: (2020)

Breaking the Invisible Barriers: Unleashing the Full Potential of Immune Checkpoint Inhibitors in Oncogene-Driven Lung Adenocarcinoma
por: Kwok, Hoi-Hin, et al.
Publicado: (2023)

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
por: Ruan, Ruiwen, et al.
Publicado: (2023)

Focused ultrasound-mediated small-molecule delivery to potentiate immune checkpoint blockade in solid tumors
por: Wu, Qiuyu, et al.
Publicado: (2023)

A model-informed approach to assess the risk of immune checkpoint inhibitor-induced autoimmune myocarditis
por: van der Vegt, Solveig A., et al.
Publicado: (2022)

Modulation of intrinsic inhibitory checkpoints using nano‐carriers to unleash NK cell activity
por: Biber, Guy, et al.
Publicado: (2021)

How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy
por: Spallarossa, Paolo, et al.
Publicado: (2020)

Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature
por: Albarrán, Víctor, et al.
Publicado: (2022)

The correlation between probiotic use and outcomes of cancer patients treated with immune checkpoint inhibitors
por: Zhang, Lilong, et al.
Publicado: (2022)

Neutrophil-related genes predict prognosis and response to immune checkpoint inhibitors in bladder cancer
por: Yang, Rui, et al.
Publicado: (2022)

Zhilong Huoxue Tongyu Capsules' Effects on ischemic stroke: An assessment using fecal 16S rRNA gene sequencing and untargeted serum metabolomics
por: Wang, Raoqiong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hf8nquugg9n3htoa8r04q3q9da